SEC Form 4 · accession 0001209191-17-022296
BIOCEPT INC · BIOC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael W. Nall
Officer — CEO & President · Director
Period of report
Mar 21, 2017
Accepted (ET)
Mar 22, 2017 · 4:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001044378
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee stock option (right to buy)F1 | $6.03 | Mar 21, 2017 | A | 6,333 | A | Mar 21, 2017 | Aug 30, 2025 | Common Stock | 6,333 | 6,333 | D |
| Employee stock option (right to buy)F2 | $4.02 | Mar 21, 2017 | A | 10,000 | A | Mar 21, 2017 | Feb 28, 2026 | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1On August 31, 2015, the reporting person was granted an option to purchase shares of the Issuer's common stock that was to vest upon the achievement of corporate goals. On March 21, 2017, the Issuer's Board of Directors confirmed the achievement of such goals.
- F2On February 29, 2016, the reporting person was granted an option to purchase shares of the Issuer's common stock that was to vest upon the achievement of corporate goals. On March 21, 2017, the Issuer's Board of Directors confirmed the achievement of such goals.